{"title": "Schlafapnoe, obstruktiv", "author": null, "url": null, "hostname": null, "description": "A trial to learn more about how well BAY2586116 works and how safe it is in participants with moderate to severe obstructive sleep apnea...", "sitename": "Bayer \u2013 Clinical Trials Explorer", "date": "2019-01-01", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Trial Condition(s):\nA trial to learn more about how well BAY2586116 works and how safe it is in participants with moderate to severe obstructive sleep apnea (SPRAY-SMART)\n20849\nNot Available\nDie Forscher suchen nach einem besseren Weg, um Menschen mit obstruktiver Schlafapnoe (OSA) zu behandeln. Bei Menschen mit OSA k\u00f6nnen sich die oberen Atemwege im Schlaf wiederholt verengen oder schlie\u00dfen. Diese Atemunterbrechungen f\u00fchren zu einer Verringerung des Sauerstoffgehalts im Blut oder zu kurzem Erwachen aus dem Schlaf. Bevor ein Medikament zur Behandlung von Menschen zugelassen werden kann, f\u00fchren Wissenschaftler klinische Pr\u00fcfungen durch, um dessen Sicherheit und Wirkungsweise besser beurteilen zu k\u00f6nnen.\nIn dieser Pr\u00fcfung m\u00f6chten die Forscher mehr dar\u00fcber erfahren, wie gut BAY2586116 bei einer kleinen Anzahl von Teilnehmern mit OSA wirkt. Die Pr\u00fcfung wird etwa 160 M\u00e4nner und Frauen einschlie\u00dfen, die mindestens 18 Jahre alt sind. Frauen k\u00f6nnen nur in diese Pr\u00fcfung aufgenommen werden, wenn sie auf nat\u00fcrliche Weise keine Kinder bekommen k\u00f6nnen.\nAn dieser Pr\u00fcfung nehmen die Teilnehmer BAY2586116 und ein Scheinmedikament ein. Ein Scheinmedikament sieht wie ein Behandlungsmedikament aus, enth\u00e4lt aber keinen Wirkstoff. Alle Teilnehmer nehmen BAY2586116 durch ein Nasenspray ein. Sie werden auch das Scheinmedikament als Nasenspray einnehmen.\nDies wird eine Crossover-Pr\u00fcfung sein. Das bedeutet, dass alle Teilnehmer beide Pr\u00fcfungsbehandlungen nacheinander, jedoch in einer anderen Reihenfolge, erhalten. Die Teilnehmer werden jede Behandlung 7 Tage lang einmal t\u00e4glich durchf\u00fchren.\nDie Forscher werden eine Messung namens Apnoe-Hypopnoe-Index (AHI) anwenden, um den Schweregrad der OSA der Teilnehmer zu messen. Die Forscher vergleichen die AHI-Werte der Teilnehmer, wenn sie BAY2586116 einnehmen und wenn sie das Scheinmedikament einnehmen.\nW\u00e4hrend der Studie besuchen die Teilnehmer ihr Pr\u00fcfzentrum 5 Mal. Bei diesen Besuchen werden die \u00c4rzte auch Blutproben entnehmen, k\u00f6rperliche Untersuchungen durchf\u00fchren und die Herzgesundheit der Teilnehmer anhand von Elektrokardiographie (EKG) pr\u00fcfen. Sie werden sich auch bei den Teilnehmern erkundigen, wie sie sich f\u00fchlen und ob sie irgendwelche medizinischen Probleme haben. Bei 3 der Besuche bleiben die Teilnehmer \u00fcber Nacht im Pr\u00fcfzentrum. Bei diesen Besuchen berechnen die \u00c4rzte pro Stunde Schlaf, wie oft die Atmung der Teilnehmer unterbricht. Nach der Behandlung f\u00fchren die Teilnehmer 7 Tage sp\u00e4ter einen letzten Besuch durch, damit die \u00c4rzte ihre Gesundheit \u00fcberpr\u00fcfen k\u00f6nnen.\n- A participant must be at least 18 years of age, at the time of signing the informed consent. - Participants need to be diagnosed with OSA. - 15 \u2264 AHI \u2264 60 per hour documented by baseline PSG (evaluated by NOX software; manual overreading by site staff possible) and after \u226572 hours of stop of specific OSA therapy. (One re-testing allowed if e.g. sleep time is less than 4 hours or e.g. due to technical problems with PSG measurement). - Male and/or female with non-childbearing potential. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. -- Male participants: Men of reproductive potential must agree to use at least two adequate contraception methods when sexually active. -- Female participants: Female participants must be of non-childbearing potential, i.e. post-menopausal (no menses for at least 1 year) or surgically sterile (tubal ligation, hysterectomy, bilateral salpingectomy or bilateral oophorectomy). - Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. - Ability to understand and follow study-related instructions. - Informed consent must be signed before any study specific tests or procedures are done.\n- Not predominantly OSA evidenced at baseline, as judged by the investigator. - Severely impaired breathing within two days prior to randomization (e.g. acute nasal congestion during upper airway infection). - Participant with known allergies or hypersensitivities to the study interventions (active substances or excipients of the preparations). Known severe respiratory tract allergies e.g. allergic asthma. - Suspected or proven active SARS-CoV-2 infection, as judged by the investigator - Subjects with a clinical diagnosis of chronic heart failure with New York Heart Association (NYHA) class III \u2013 IV as judged by the investigator at screening visit. - Uncontrolled arterial hypertension with diastolic blood pressure (DBP) >110 mmHg or systolic blood pressure (SBP) >180 mmHg at screening visit. - Chronic obstructive pulmonary disease (COPD) with more than one exacerbation during the last 12 months prior to screening visit. - Previous assignment to a study intervention during this study. - Participation in another trial with an investigational drug within 30 days or 5 half-lives of the investigational drug, whichever is longer before first application of study intervention or concomitant participation in another clinical study with investigational medicinal product(s). - Heavy smoking, i.e. more than 20 cigarettes or equivalent per day and/or unable to stop smoking during the stay in the sleep laboratory. - Suspicion of drug or alcohol abuse. - Regular daily consumption of more than 1 L of xanthine-containing beverages. - Inability to comply with planned study procedures or to comply with study protocol requirements; this includes completing required data collection and attending required end of study/follow up study visits. - Any other condition, which would make the participant unsuitable for this study and will not allow participation for the full planned study period (e.g. active malignancy or other condition limiting life expectancy to less than 12 months). - Close affiliation with the investigational site; e.g. a close relative of the investigator, dependent person (e.g. employee or student of the investigational site).\n|Studienstandorte|\nStudienstandorte\nRuhrlandklinik, Westdeutsches Lungenzentrum\nEssen, Germany, 45239\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nUniversit\u00e4tsSpital Z\u00fcrich\nZ\u00fcrich, Switzerland, 8091\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nStudienstandorte\nAdvanced Sleep Research GmbH\nBerlin, Germany, 10117\nContact Us:\nE-mail:\nPhone: (+)1-888-84 22937\nProof-of-concept, multi-center, randomized, double-blind, placebo-controlled, two-way crossover study to investigate the effect strength of BAY 2586116 on the apnea-hypopnea-index after repetitive nasal doses compared to placebo in 80 valid participants with moderate to severe obstructive sleep apnea\nTrial Type:\nInterventional\nIntervention Type:\nDrug\nTrial Purpose:\nTreatment\nAllocation:\nRandomized\nBlinding:\nN/A\nAssignment:\nCrossover Assignment\nTrial Arms:\n2", "language": null, "image": "https://clinicaltrials.bayer.com/images/clinical_trials_explorer_logo.png", "pagetype": "website", "links": ["/", "/why-participate", "/#enhancingDiversity", "/what-are-clinical-trials", "/what-to-expect", "/transparency-policy", "https://www.facebook.com/sharer/sharer.php?u=", "https://twitter.com/share?url=", "https://www.linkedin.com/shareArticle?mini=true&url=", "/cdn-cgi/l/email-protection#dde2aea8bfb7b8bea9e09fbca4b8affdaea9a8b9a4fdb2b3fd91a8b3baaefdfbbcb0ade6fd8fb8aeadb4afbca9b2afa4fdf0fd92a9b5b8affbbcb0ade6bfb2b9a4e094fdb7a8aea9fdbbb2a8b3b9fda9b5bca9fd9fbca4b8affdb5bcaefdbcfdaea9a8b9a4fdbbb2affdadb8b2adb1b8fdaab4a9b5fd91a8b3baaefdfbbcb0ade6fd8fb8aeadb4afbca9b2afa4fdf0fd92a9b5b8aff8ed99f8ed9c84b2a8fdbebcb3fdb1b8bcafb3fdb0b2afb8fdbfa4fdbeb1b4beb6b4b3bafdb2b3fda9b5b8fdb1b4b3b6fdbfb8b1b2aaf3fd", "https://clinicaltrials.gov/ct2/show/?term=NCT04713826&rank=1", "https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-000520-19", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "/cdn-cgi/l/email-protection", "https://www.facebook.com/pharma.bayer/", "https://twitter.com/bayerpharma", "https://www.youtube.com/bayerpharma", "/terms-use", "/privacy-statement", "/contact-us", "/transparency-policy", "/sitemap"]}